source
- Ultragenyx sells priority review voucher for $210 million, retains another to monetizeUltragenyx Pharmaceutical announced it has sold a priority review voucher to an undisclosed buyer for $210 million. The transaction is among the highest-priced voucher sales this year, providing a…
- WHO advises against GLP-1 obesity drugs for children under 10, limits use in teensThe World Health Organization issued guidance recommending that GLP-1 drugs not be used to treat obesity in children younger than ten years old. For adolescents aged 10 to 19, the WHO says these m…